Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Zhijie Wang,Lin Wu,Baolan Li,Ying Cheng,Xiaoling Li,Xicheng Wang,Liang Han,Xiaohong Wu,Yun Fan,Yan Yu,Dongqing Lv,Jianhua Shi,Jianjin Huang,Shaozhang Zhou,Baohui Han,Guogui Sun,Qisen Guo,Youxin Ji,Xiaoli Zhu,Sheng Hu,Wei Zhang,Qiming Wang,Yuming Jia,Ziping Wang,Yong Song,Jingxun Wu,Meiqi Shi,Xingya Li,Zhigang Han,Yunpeng Liu,Zhuang Yu,An-Wen Liu,Xiuwen Wang,Caicun Zhou,Diansheng Zhong,Liyun Miao,Zhihong Zhang,Hui Zhao,Jun Yang,Dong Wang,Yingyi Wang,Qiang Li,Xiaodong Zhang,Mei Ji,Zhenzhou Yang,Jiuwei Cui,Beili Gao,Buhai Wang,Hu Liu,Lei Nie,Mei He,Shi Jin,Wei Gu,Yongqian Shu,Tong Zhou,Jian Feng,Xinmei Yang,Cheng Huang,Bo Zhu,Yu Yao,Xiongwen Tang,Jianjun Yu,Ellen Maher,Hui Feng,Sheng Yao,Patricia Keegan,Jie Wang
DOI: https://doi.org/10.1200/JCO.22.00727
2023-01-20
Abstract:Purpose: The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). Patients and methods: Patients (N = 465) with treatment-naive, advanced NSCLC without EGFR/ALK mutations were randomly assigned 2:1 to receive toripalimab 240 mg (n = 309) or placebo (n = 156) once every 3 weeks in combination with chemotherapy for 4-6 cycles, followed by the maintenance of toripalimab or placebo once every 3 weeks plus standard care. Stratification factors included programmed death ligand-1 expression status, histology, and smoking status. The primary end point was progression-free survival (PFS) by investigator per RECIST v1.1. Secondary end points included overall survival and safety. Results: At the final PFS analysis, PFS was significantly longer in the toripalimab arm than in the placebo arm (median PFS, 8.4 v 5.6 months, hazard ratio = 0.49; 95% CI, 0.39 to 0.61; two-sided P < .0001). At the interim OS analysis, the toripalimab arm had a significantly longer OS than the placebo arm (median OS not reached v 17.1 months, hazard ratio = 0.69; 95% CI, 0.53 to 0.92; two-sided P = .0099). The incidence of grade ≥ 3 adverse events was similar between the two arms. Treatment effects were similar regardless of programmed death ligand-1 status. Genomic analysis using whole-exome sequencing from 394 available tumor samples revealed that patients with high tumor mutational burden were associated with significantly better PFS in the toripalimab arm (median PFS 13.1 v 5.5 months, interaction P = .026). Notably, patients with mutations in the focal adhesion-PI3K-Akt signaling pathway achieved significantly better PFS and OS in the toripalimab arm (interaction P values ≤ .001). Conclusion: Toripalimab plus chemotherapy significantly improves PFS and OS in patients with treatment-naive advanced NSCLC while having a manageable safety profile. Subgroup analysis showed the OS benefit was mainly driven by the nonsquamous subpopulation.